01 / Findings for weight, the heart and kidneys
Semaglutide trials found weight loss plus fewer serious illnesses
Scientists changed GLP-1, a hormone helping control sugar and hunger, so semaglutide would last longer. People lost weight in trials. Other tests found fewer major problems with the heart or with the kidneys.
The main benefits were tested in separate groups of people
Scientists made semaglutide by changing GLP-1, a hormone carrying messages about sugar and hunger. The changes help the drug last longer in the body. Approved semaglutide products include Rybelsus, Ozempic and Wegovy. The products have different approved uses, so a claim must name the actual treatment.
The weight trial called STEP 1 followed people for 68 weeks [4]. SELECT tested 17,604 adults who had heart disease before treatment and carried extra weight. They didn't have diabetes [3]. FLOW tested 3,533 people with type 2 diabetes whose kidney disease was long-lasting [2].
Those studies measured weight and serious illnesses in the people tested, but you need the harms that occurred among those same people while they took the medicine. Reviews found stomach trouble, gallbladder disease in the sac holding digestive fluid, and worse eye disease from diabetes in some patients [5][7]. The benefits don't remove those risks or settle every new treatment claim.
Changes to semaglutide help the medicine last longer
Semaglutide has a 31-amino-acid makeup, joining the tiny parts used in proteins. About 94% match the parts in your body's natural GLP-1 hormone. Scientists changed parts that would otherwise break down quickly. They added a fatty part that helps the drug attach to blood protein.
That attachment slows the body's removal of semaglutide from the blood. The medicine lasts longer than the hormone released after food, but FDA review still considers the exact drug being given, how that drug is made and what the drug treats. Another bottle's name doesn't establish that the contents will act the same way in you.
Approved uses include type 2 diabetes and certain long-term weight needs. Other uses concern heart risk and liver disease linked to sugar and fat. That broad liver wording leaves your own liver illness’s approval unanswered. A trial comparing semaglutide directly with tirzepatide gives firmer weight evidence than comparing separate studies [1].
Eating less helps explain the weight changes in trials
GLP-1 helps control hunger and sugar after you eat. Semaglutide copies GLP-1 and helps release insulin as the sugar level rises. Insulin lowers sugar in the blood; glucagon is a hormone that raises sugar, and the drug reduces needless glucagon release. Food also stays longer in the stomach, which can affect sugar readings and cause stomach trouble.
Researchers found semaglutide within brain areas involved in eating in rats and mice. Those animals chose different foods and ate less [6]. The animals' bodies didn't use less energy in that experiment. Animal results help explain eating changes, but can't establish weight loss in people.
STEP 1 tested people's weight, assigning treatments by chance [4]. That human trial supplies the weight finding you can read below. SELECT counted serious heart problems, and FLOW counted serious kidney problems [2][3]. The separate questions matter because one benefit doesn't establish another benefit for you.
Weight fell and heart and kidney problems happened less often
Weight without diabetes. STEP 1 tested 1,961 adults with excess weight or obesity but no diabetes. By week 68, average weight changes were −14.9% with semaglutide and −2.4% with placebo, an inactive treatment used for comparison. Both minus signs mean weight was lost. The semaglutide group had greater weight loss than the group without the drug [4].
Weight against another drug. SURMOUNT-5 followed 751 adults with obesity for 72 weeks. Weight changed on average by −13.7% with semaglutide and −20.2% with tirzepatide [1]. Tirzepatide produced greater loss, beyond what chance alone would readily explain. An average for the groups can't choose the medicine that suits you.
Heart attacks, strokes and heart-related deaths. SELECT tested 17,604 adults who had heart disease before treatment and carried extra weight, without diabetes. These problems happened less often in the semaglutide group [3]. Researchers used a 95% confidence range, an allowance for uncertainty about the size of the benefit. Even with that uncertainty, the result pointed to a heart benefit.
Serious kidney trouble. FLOW tested 3,533 people with type 2 diabetes whose kidney disease was long-lasting. Major kidney problems happened less often with semaglutide than placebo [2]. The researchers' 95% confidence range allowed for uncertainty and still pointed to benefit. That check doesn't give your personal chance of avoiding kidney trouble.
Heart benefit alongside eye harm. SUSTAIN-6 found fewer major heart problems but more eye complications from diabetes [7]. The same drug can help one part of your health and harm another. Your existing eye problems matter when weighing that result. A good heart finding can't cancel the eye concern.
Stomach and eye problems need attention alongside the benefits
People using semaglutide for research share experiences, not findings tested through a fair treatment comparison; patients share accounts too. Some describe fewer thoughts about eating or feeling full earlier. Others mention less craving, weight changes or better sugar readings. Nausea and vomiting also appear in those accounts.
Other accounts describe bowel changes, tiredness, taste changes, headaches and hair shedding. Reflux means stomach contents rise toward the throat and cause burning. Some people mention soreness after a shot. You can't use volunteered reports to count everyone's risks or link every reported problem to the drug.
A safety review found mostly mild or moderate stomach problems that passed [5]. About a third reported nausea, and gallbladder illness increased. Gallbladders store digestive fluid; the pancreas helps digest food and control sugar, while the thyroid gland helps control the body’s use of energy. Too few cancers of the pancreas or thyroid occurred to settle those concerns, and eye harm was greater when eyes were already damaged and sugar fell quickly [7].
The strong warning about thyroid tumors comes from rats and mice [5]. The reviewed research hasn't established that cancer link in people. Sudden inflammation of the pancreas remains a warning; gallbladder disease remains a concern [5]. You need both the benefits and these cautions to weigh semaglutide treatment.
Semaglutide has more kinds of human trial findings here
Semaglutide has the widest range of large human trials among these four drugs. The evidence covers different health problems in different groups. Tirzepatide copies another food-related hormone and produced greater weight loss in a direct comparison [1]. Tesamorelin increases growth hormone, while bremelanotide treats certain women troubled by their lost desire.
These medicines can't be exchanged merely because all are peptides. Your reason for treatment needs to match the evidence for that drug. A name on research material doesn't establish approval, contents or strength. Claims beyond a medicine's tested use still need trials of their own.